Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23242608)

1.

PTEN protein expression in malignant pleural mesothelioma.

Agarwal V, Campbell A, Beaumont KL, Cawkwell L, Lind MJ.

Tumour Biol. 2013 Apr;34(2):847-51. doi: 10.1007/s13277-012-0615-9. Epub 2012 Dec 15.

PMID:
23242608
2.

PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.

Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder W, Opitz I.

J Thorac Oncol. 2014 Feb;9(2):239-47. doi: 10.1097/JTO.0000000000000055.

PMID:
24419422
3.

Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).

Cedrés S, Montero MA, Martinez P, Martinez A, Rodríguez-Freixinós V, Torrejon D, Gabaldon A, Salcedo M, Ramon Y Cajal S, Felip E.

Lung Cancer. 2012 Jul;77(1):192-8. doi: 10.1016/j.lungcan.2012.02.022. Epub 2012 Mar 27.

PMID:
22459204
4.

Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.

Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD.

Histopathology. 2002 Jul;41(1):42-9.

PMID:
12121236
5.

Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.

Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, Soltermann A.

Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72. doi: 10.1016/j.ejcts.2009.08.027. Epub 2009 Sep 24.

PMID:
19781955
6.

PTEN expression is a strong predictor of survival in mesothelioma patients.

Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W.

Eur J Cardiothorac Surg. 2008 Mar;33(3):502-6. doi: 10.1016/j.ejcts.2007.09.045. Epub 2008 Jan 8.

PMID:
18248818
7.

Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.

Jennings CJ, O'Grady A, Cummins R, Murer B, Al-Alawi M, Madden SF, Mutti L, Harvey BJ, Thomas W, Kay EW.

J Thorac Oncol. 2012 Jan;7(1):243-8. doi: 10.1097/JTO.0b013e31822f6544.

PMID:
22011668
8.

Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Hmeljak J, Erčulj N, Dolžan V, Pižem J, Kern I, Kovač V, Cemažar M, Cör A.

Virchows Arch. 2013 Mar;462(3):315-21. doi: 10.1007/s00428-013-1373-9. Epub 2013 Jan 29.

PMID:
23358691
9.

Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.

Shia J, Qin J, Erlandson RA, King R, Illei P, Nobrega J, Yao D, Klimstra DS.

Virchows Arch. 2005 Nov;447(5):828-34. Epub 2005 Jul 14.

PMID:
16021506
10.

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, Inai K.

Oncol Rep. 2013 Jan;29(1):21-8. doi: 10.3892/or.2012.2116. Epub 2012 Oct 31.

12.

Immunohistochemical MIB-1 and p27 as prognostic factors in pleural mesothelioma.

Beer TW.

Pathol Res Pract. 2001;197(12):859. No abstract available.

PMID:
11795837
13.

Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.

Rena O, Boldorini LR, Gaudino E, Casadio C.

J Surg Oncol. 2011 Nov 1;104(6):701-5. doi: 10.1002/jso.21901. Epub 2011 Mar 21.

PMID:
21437912
14.

Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma.

Iwanami T, Uramoto H, Nakagawa M, Shimokawa H, Yamada S, Kohno K, Tanaka F.

Oncology. 2014;86(2):109-16. doi: 10.1159/000356874. Epub 2014 Jan 21.

PMID:
24457449
15.

Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.

Klebe S, Mahar A, Henderson DW, Roggli VL.

Mod Pathol. 2008 Sep;21(9):1084-94. doi: 10.1038/modpathol.2008.125. Epub 2008 Jun 27.

16.

Over-expression of tenascin-C in malignant pleural mesothelioma.

Kaarteenaho-Wiik R, Soini Y, Pöllänen R, Pääkkö P, Kinnula VL.

Histopathology. 2003 Mar;42(3):280-91.

PMID:
12605648
17.

Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.

O'Kane SL, Cawkwell L, Campbell A, Lind MJ.

Eur J Cancer. 2005 Jul;41(11):1645-8.

PMID:
15964184
18.

Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases.

Galateau-Sallé F, Attanoos R, Gibbs AR, Burke L, Astoul P, Rolland P, Ilg AG, Pairon JC, Brochard P, Begueret H, Vignaud JM, Kerr K, Launoy G, Imbernon E, Goldberg M.

Am J Surg Pathol. 2007 May;31(5):711-6.

PMID:
17460454
19.

Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.

Lindholm PM, Soini Y, Myllärniemi M, Knuutila S, Heikinheimo M, Kinnula VL, Salmenkivi K.

J Clin Pathol. 2009 Apr;62(4):339-44. doi: 10.1136/jcp.2008.060533. Epub 2008 Dec 5.

PMID:
19060016
20.

Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.

Leonardo E, Zanconati F, Bonifacio D, Bonito LD.

Pathol Res Pract. 2001;197(4):253-6.

PMID:
11358011
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk